What does this research mean for the field?

A combination of white and red frangipani flower extracts significantly reduces blood glucose levels in diabetic mice, potentially through the binding of the metabolite Plumericin to the SGLT-2 receptor. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to assess the antidiabetic and antioxidant effects of white and red frangipani extracts.

May 19, 2026Open Access

In vivo Antidiabetic Effect of White Frangipani (Plumeria acuminata L.) and Red Frangipani (Plumeria rubra L.) Flower Extracts and Computational Analysis on SGLT-2 Receptor

Key Points

This research aims to assess the antidiabetic and antioxidant effects of white and red frangipani extracts.
Alloxan-induced diabetic mice received white frangipani extract (200 mg/kgBW) and red frangipani extract (400 mg/kgBW).
Oral Glucose Tolerance Test (OGTT) showed significant reductions in blood glucose levels.
In silico docking analysis evaluated the binding affinity of plumericin to the SGLT-2 receptor.
The combination of WFE and RFE reduced blood glucose by 57.7%.
OGTT method showed a 71.3% reduction with the specified doses, indicating effectiveness.
Plumericin displayed a high binding affinity to SGLT-2 receptor (-9.36 kcal/mol), suggesting therapeutic potential.

Abstract

Diabetes Mellitus (DM) is a metabolic disorder marked by hyperglycemia, often necessitating alternatives to long-term medications due to side effects. This study evaluates the antioxidant and anti-diabetic potential of white frangipani (Plumeria acuminata L. ) and red frangipani (Plumeria rubra L. ) extracts. In alloxan-induced diabetic mice, a combination of white frangipani extract (WFE) 200 mg/kgBW and red frangipani extract (RFE) 400 mg/kgBW reduced blood glucose by 57. 7%, while a dose of WFE 400 mg/kgBW and RFE 400 mg/kgBW in the OGTT method resulted in a 71. 3% reduction. The extracts significantly reduced glucose levels compared to the Negative Control, with no significant difference from the Positive Control group (p0. 05). In silicodocking analysis revealed that Plumericin, a major metabolite, had high binding affinity to the SGLT-2 receptor (-9. 36 kcal/mol), close to the native ligand (-11. 46 kcal/mol). Molecular dynamics simulations confirmed the Plumericin-SGLT-2 complex's stability, supporting the therapeutic potential of these extracts for DM treatment. This dual In vivo and in silico approach provides a comprehensive understanding of their therapeutic potential and supports further exploration of these extracts as candidates for diabetes treatment

Bookmark

View Full Paper